APO Research
Talk to an analyst

APO RESEARCH · REPORT

Non-Insulin Hypoglycemic Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Non-Insulin Hypoglycemic Drug Industry Research Report 2026

29 December 2025138 pages

Choose your research edition.

Industry ResearchNon-Insulin Hypoglycemic Drug Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Non-Insulin Hypoglycemic Drug Industry Growth and Trends Forecast to 2032118 pages · $3,450 USDMarket StructureGlobal Non-Insulin Hypoglycemic Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Non-Insulin Hypoglycemic Drug Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Non-Insulin Hypoglycemic Drug Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Non-Insulin Hypoglycemic Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Non-Insulin Hypoglycemic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Non-Insulin Hypoglycemic Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Non-Insulin Hypoglycemic Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Non-Insulin Hypoglycemic Drug include GSK, Takeda, Merck, Uni-Bio Science Group, Eli Lilly, Jiangsu Hengrui Medicine, Jiangsu Hansoh Pharmaceutical, Pfizer and Sumitomo Dainippon Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Non-Insulin Hypoglycemic Drug market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Non-Insulin Hypoglycemic Drug Market by Company

GSK

Takeda

Merck

Uni-Bio Science Group

Eli Lilly

Jiangsu Hengrui Medicine

Jiangsu Hansoh Pharmaceutical

Pfizer

Sumitomo Dainippon Pharma

Servier

Novo Nordisk

Luye Pharma Group

Intarcia Therapeutics

Geropharm

Eurofarma

Emisphere

Dong-A Pharmaceutical

Alkem Labs

3SBio

Non-Insulin Hypoglycemic Drug Segment by Type

Alpha Glucosidase Inhibitors

Meglitinides

Sulfonylureas

Thiazolidinediones

Biguanides

Others

Non-Insulin Hypoglycemic Drug Segment by Application

Hospital Pharmacies

Retail Pharmacies

Non-Insulin Hypoglycemic Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non-Insulin Hypoglycemic Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Non-Insulin Hypoglycemic Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non-Insulin Hypoglycemic Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Non-Insulin Hypoglycemic Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Non-Insulin Hypoglycemic Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Non-Insulin Hypoglycemic Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Non-Insulin Hypoglycemic Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Non-Insulin Hypoglycemic Drug Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global Non-Insulin Hypoglycemic Drug Revenue of Manufacturers (2021-2026) Table 9. Global Non-Insulin Hypoglycemic Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Non-Insulin Hypoglycemic Drug Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Non-Insulin Hypoglycemic Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Non-Insulin Hypoglycemic Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Non-Insulin Hypoglycemic Drug, Product Type & Application Table 14. Global Non-Insulin Hypoglycemic Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Non-Insulin Hypoglycemic Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. GSK Company Information Table 19. GSK Business Overview Table 20. GSK Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. GSK Non-Insulin Hypoglycemic Drug Product Portfolio Table 22. GSK Recent Developments Table 23. Takeda Company Information Table 24. Takeda Business Overview Table 25. Takeda Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Takeda Non-Insulin Hypoglycemic Drug Product Portfolio Table 27. Takeda Recent Developments Table 28. Merck Company Information Table 29. Merck Business Overview Table 30. Merck Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Merck Non-Insulin Hypoglycemic Drug Product Portfolio Table 32. Merck Recent Developments Table 33. Uni-Bio Science Group Company Information Table 34. Uni-Bio Science Group Business Overview Table 35. Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Product Portfolio Table 37. Uni-Bio Science Group Recent Developments Table 38. Eli Lilly Company Information Table 39. Eli Lilly Business Overview Table 40. Eli Lilly Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Eli Lilly Non-Insulin Hypoglycemic Drug Product Portfolio Table 42. Eli Lilly Recent Developments Table 43. Jiangsu Hengrui Medicine Company Information Table 44. Jiangsu Hengrui Medicine Business Overview Table 45. Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Product Portfolio Table 47. Jiangsu Hengrui Medicine Recent Developments Table 48. Jiangsu Hansoh Pharmaceutical Company Information Table 49. Jiangsu Hansoh Pharmaceutical Business Overview Table 50. Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Product Portfolio Table 52. Jiangsu Hansoh Pharmaceutical Recent Developments Table 53. Pfizer Company Information Table 54. Pfizer Business Overview Table 55. Pfizer Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Pfizer Non-Insulin Hypoglycemic Drug Product Portfolio Table 57. Pfizer Recent Developments Table 58. Sumitomo Dainippon Pharma Company Information Table 59. Sumitomo Dainippon Pharma Business Overview Table 60. Sumitomo Dainippon Pharma Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Sumitomo Dainippon Pharma Non-Insulin Hypoglycemic Drug Product Portfolio Table 62. Sumitomo Dainippon Pharma Recent Developments Table 63. Servier Company Information Table 64. Servier Business Overview Table 65. Servier Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Servier Non-Insulin Hypoglycemic Drug Product Portfolio Table 67. Servier Recent Developments Table 68. Novo Nordisk Company Information Table 69. Novo Nordisk Business Overview Table 70. Novo Nordisk Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Novo Nordisk Non-Insulin Hypoglycemic Drug Product Portfolio Table 72. Novo Nordisk Recent Developments Table 73. Luye Pharma Group Company Information Table 74. Luye Pharma Group Business Overview Table 75. Luye Pharma Group Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Luye Pharma Group Non-Insulin Hypoglycemic Drug Product Portfolio Table 77. Luye Pharma Group Recent Developments Table 78. Intarcia Therapeutics Company Information Table 79. Intarcia Therapeutics Business Overview Table 80. Intarcia Therapeutics Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Intarcia Therapeutics Non-Insulin Hypoglycemic Drug Product Portfolio Table 82. Intarcia Therapeutics Recent Developments Table 83. Geropharm Company Information Table 84. Geropharm Business Overview Table 85. Geropharm Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Geropharm Non-Insulin Hypoglycemic Drug Product Portfolio Table 87. Geropharm Recent Developments Table 88. Eurofarma Company Information Table 89. Eurofarma Business Overview Table 90. Eurofarma Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Eurofarma Non-Insulin Hypoglycemic Drug Product Portfolio Table 92. Eurofarma Recent Developments Table 93. Emisphere Company Information Table 94. Emisphere Business Overview Table 95. Emisphere Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Emisphere Non-Insulin Hypoglycemic Drug Product Portfolio Table 97. Emisphere Recent Developments Table 98. Dong-A Pharmaceutical Company Information Table 99. Dong-A Pharmaceutical Business Overview Table 100. Dong-A Pharmaceutical Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Dong-A Pharmaceutical Non-Insulin Hypoglycemic Drug Product Portfolio Table 102. Dong-A Pharmaceutical Recent Developments Table 103. Alkem Labs Company Information Table 104. Alkem Labs Business Overview Table 105. Alkem Labs Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Alkem Labs Non-Insulin Hypoglycemic Drug Product Portfolio Table 107. Alkem Labs Recent Developments Table 108. 3SBio Company Information Table 109. 3SBio Business Overview Table 110. 3SBio Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. 3SBio Non-Insulin Hypoglycemic Drug Product Portfolio Table 112. 3SBio Recent Developments Table 113. Global Non-Insulin Hypoglycemic Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 114. Global Non-Insulin Hypoglycemic Drug Sales by Region (2021-2026) & (K Units) Table 115. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Region (2021-2026) Table 116. Global Non-Insulin Hypoglycemic Drug Sales by Region (2027-2032) & (K Units) Table 117. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Region (2027-2032) Table 118. Global Non-Insulin Hypoglycemic Drug Revenue by Region (2021-2026) & (US$ Million) Table 119. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Region (2021-2026) Table 120. Global Non-Insulin Hypoglycemic Drug Revenue by Region (2027-2032) & (US$ Million) Table 121. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Region (2027-2032) Table 122. North America Non-Insulin Hypoglycemic Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. North America Non-Insulin Hypoglycemic Drug Sales by Country (2021-2026) & (K Units) Table 124. North America Non-Insulin Hypoglycemic Drug Sales by Country (2027-2032) & (K Units) Table 125. North America Non-Insulin Hypoglycemic Drug Revenue by Country (2021-2026) & (US$ Million) Table 126. North America Non-Insulin Hypoglycemic Drug Revenue by Country (2027-2032) & (US$ Million) Table 127. Europe Non-Insulin Hypoglycemic Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Europe Non-Insulin Hypoglycemic Drug Sales by Country (2021-2026) & (K Units) Table 129. Europe Non-Insulin Hypoglycemic Drug Sales by Country (2027-2032) & (K Units) Table 130. Europe Non-Insulin Hypoglycemic Drug Revenue by Country (2021-2026) & (US$ Million) Table 131. Europe Non-Insulin Hypoglycemic Drug Revenue by Country (2027-2032) & (US$ Million) Table 132. Asia Pacific Non-Insulin Hypoglycemic Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. Asia Pacific Non-Insulin Hypoglycemic Drug Sales by Country (2021-2026) & (K Units) Table 134. Asia Pacific Non-Insulin Hypoglycemic Drug Sales by Country (2027-2032) & (K Units) Table 135. Asia Pacific Non-Insulin Hypoglycemic Drug Revenue by Country (2021-2026) & (US$ Million) Table 136. Asia Pacific Non-Insulin Hypoglycemic Drug Revenue by Country (2027-2032) & (US$ Million) Table 137. South America Non-Insulin Hypoglycemic Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. South America Non-Insulin Hypoglycemic Drug Sales by Country (2021-2026) & (K Units) Table 139. South America Non-Insulin Hypoglycemic Drug Sales by Country (2027-2032) & (K Units) Table 140. South America Non-Insulin Hypoglycemic Drug Revenue by Country (2021-2026) & (US$ Million) Table 141. South America Non-Insulin Hypoglycemic Drug Revenue by Country (2027-2032) & (US$ Million) Table 142. Middle East and Africa Non-Insulin Hypoglycemic Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 143. Middle East and Africa Non-Insulin Hypoglycemic Drug Sales by Country (2021-2026) & (K Units) Table 144. Middle East and Africa Non-Insulin Hypoglycemic Drug Sales by Country (2027-2032) & (K Units) Table 145. Middle East and Africa Non-Insulin Hypoglycemic Drug Revenue by Country (2021-2026) & (US$ Million) Table 146. Middle East and Africa Non-Insulin Hypoglycemic Drug Revenue by Country (2027-2032) & (US$ Million) Table 147. Global Non-Insulin Hypoglycemic Drug Sales by Type (2021-2026) & (K Units) Table 148. Global Non-Insulin Hypoglycemic Drug Sales by Type (2027-2032) & (K Units) Table 149. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Type (2021-2026) Table 150. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Type (2027-2032) Table 151. Global Non-Insulin Hypoglycemic Drug Revenue by Type (2021-2026) & (US$ Million) Table 152. Global Non-Insulin Hypoglycemic Drug Revenue by Type (2027-2032) & (US$ Million) Table 153. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Type (2021-2026) Table 154. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Type (2027-2032) Table 155. Global Non-Insulin Hypoglycemic Drug Price by Type (2021-2026) & (US$/Unit) Table 156. Global Non-Insulin Hypoglycemic Drug Price by Type (2027-2032) & (US$/Unit) Table 157. Global Non-Insulin Hypoglycemic Drug Sales by Application (2021-2026) & (K Units) Table 158. Global Non-Insulin Hypoglycemic Drug Sales by Application (2027-2032) & (K Units) Table 159. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Application (2021-2026) Table 160. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Application (2027-2032) Table 161. Global Non-Insulin Hypoglycemic Drug Revenue by Application (2021-2026) & (US$ Million) Table 162. Global Non-Insulin Hypoglycemic Drug Revenue by Application (2027-2032) & (US$ Million) Table 163. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Application (2021-2026) Table 164. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Application (2027-2032) Table 165. Global Non-Insulin Hypoglycemic Drug Price by Application (2021-2026) & (US$/Unit) Table 166. Global Non-Insulin Hypoglycemic Drug Price by Application (2027-2032) & (US$/Unit) Table 167. Key Raw Materials Table 168. Raw Materials Key Suppliers Table 169. Non-Insulin Hypoglycemic Drug Distributors List Table 170. Non-Insulin Hypoglycemic Drug Customers List Table 171. Non-Insulin Hypoglycemic Drug Industry Trends Table 172. Non-Insulin Hypoglycemic Drug Industry Drivers Table 173. Non-Insulin Hypoglycemic Drug Industry Restraints Table 174. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Non-Insulin Hypoglycemic Drug Product Image Figure 5. Global Non-Insulin Hypoglycemic Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Non-Insulin Hypoglycemic Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global Non-Insulin Hypoglycemic Drug Sales (2021-2032) & (K Units) Figure 8. Global Non-Insulin Hypoglycemic Drug Average Price (US$/Unit) & (2021-2032) Figure 9. Alpha Glucosidase Inhibitors Product Image Figure 10. Meglitinides Product Image Figure 11. Sulfonylureas Product Image Figure 12. Thiazolidinediones Product Image Figure 13. Biguanides Product Image Figure 14. Others Product Image Figure 15. Hospital Pharmacies Product Image Figure 16. Retail Pharmacies Product Image Figure 17. Global Non-Insulin Hypoglycemic Drug Revenue Share by Manufacturers in 2025 Figure 18. Global Manufacturers of Non-Insulin Hypoglycemic Drug, Manufacturing Sites & Headquarters Figure 19. Global Top 5 and 10 Non-Insulin Hypoglycemic Drug Players Market Share by Revenue in 2025 Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Non-Insulin Hypoglycemic Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 22. Global Non-Insulin Hypoglycemic Drug Sales by Region in 2025 Figure 23. Global Non-Insulin Hypoglycemic Drug Revenue by Region in 2025 Figure 24. North America Non-Insulin Hypoglycemic Drug Market Size by Country in 2025 Figure 25. North America Non-Insulin Hypoglycemic Drug Sales Market Share by Country (2021-2032) Figure 26. North America Non-Insulin Hypoglycemic Drug Revenue Market Share by Country (2021-2032) Figure 27. United States Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Canada Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Europe Non-Insulin Hypoglycemic Drug Market Size by Country in 2025 Figure 30. Europe Non-Insulin Hypoglycemic Drug Sales Market Share by Country (2021-2032) Figure 31. Europe Non-Insulin Hypoglycemic Drug Revenue Market Share by Country (2021-2032) Figure 32. Germany Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. France Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. U.K. Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Italy Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Asia Pacific Non-Insulin Hypoglycemic Drug Market Size by Country in 2025 Figure 38. Asia Pacific Non-Insulin Hypoglycemic Drug Sales Market Share by Country (2021-2032) Figure 39. Asia Pacific Non-Insulin Hypoglycemic Drug Revenue Market Share by Country (2021-2032) Figure 40. China Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Japan Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. South Korea Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. India Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Australia Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. China Taiwan Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Southeast Asia Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Southeast Asia Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. South America Non-Insulin Hypoglycemic Drug Market Size by Country in 2025 Figure 49. South America Non-Insulin Hypoglycemic Drug Sales Market Share by Country (2021-2032) Figure 50. South America Non-Insulin Hypoglycemic Drug Revenue Market Share by Country (2021-2032) Figure 51. Mexico Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Brazil Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Argentina Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Middle East and Africa Non-Insulin Hypoglycemic Drug Market Size by Country in 2025 Figure 55. Middle East and Africa Non-Insulin Hypoglycemic Drug Sales Market Share by Country (2021-2032) Figure 56. Middle East and Africa Non-Insulin Hypoglycemic Drug Revenue Market Share by Country (2021-2032) Figure 57. Turkey Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Saudi Arabia Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. UAE Non-Insulin Hypoglycemic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Type (2021-2032) Figure 61. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Type (2021-2032) Figure 62. Global Non-Insulin Hypoglycemic Drug Price (US$/Unit) by Type (2021-2032) Figure 63. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Application (2021-2032) Figure 64. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Application (2021-2032) Figure 65. Global Non-Insulin Hypoglycemic Drug Price (US$/Unit) by Application (2021-2032) Figure 66. Non-Insulin Hypoglycemic Drug Value Chain Figure 67. Non-Insulin Hypoglycemic Drug Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Non-Insulin Hypoglycemic Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • Alpha Glucosidase Inhibitors
  • Meglitinides
  • Sulfonylureas
  • Thiazolidinediones
  • Biguanides
  • Others
Applications
  • Hospital Pharmacies
  • Retail Pharmacies
Companies covered
  • GSK
  • Takeda
  • Merck
  • Uni-Bio Science Group
  • Eli Lilly
  • Jiangsu Hengrui Medicine
  • Jiangsu Hansoh Pharmaceutical
  • Pfizer
  • Sumitomo Dainippon Pharma
  • Servier
  • Novo Nordisk
  • Luye Pharma Group
  • Intarcia Therapeutics
  • Geropharm
  • Eurofarma
  • Emisphere
  • Dong-A Pharmaceutical
  • Alkem Labs
  • 3SBio

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Non-Insulin Hypoglycemic Drug Market Size (2021-2032)
  4. 2.2.2 Global Non-Insulin Hypoglycemic Drug Sales (2021-2032)
  5. 2.2.3 Global Non-Insulin Hypoglycemic Drug Market Average Price (2021-2032)
  6. 2.3 Non-Insulin Hypoglycemic Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Alpha Glucosidase Inhibitors
  9. 2.3.3 Meglitinides
  10. 2.3.4 Sulfonylureas
  11. 2.3.5 Thiazolidinediones
  12. 2.3.6 Biguanides
  13. 2.3.7 Others
  14. 2.4 Non-Insulin Hypoglycemic Drug by Application
  15. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  16. 2.4.2 Hospital Pharmacies
  17. 2.4.3 Retail Pharmacies
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Non-Insulin Hypoglycemic Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Non-Insulin Hypoglycemic Drug Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Non-Insulin Hypoglycemic Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Non-Insulin Hypoglycemic Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Non-Insulin Hypoglycemic Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Non-Insulin Hypoglycemic Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Non-Insulin Hypoglycemic Drug, Product Type & Application
  8. 3.8 Global Manufacturers of Non-Insulin Hypoglycemic Drug, Established Date
  9. 3.9 Global Non-Insulin Hypoglycemic Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 GSK
  2. 4.1.1 GSK Company Information
  3. 4.1.2 GSK Business Overview
  4. 4.1.3 GSK Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 GSK Non-Insulin Hypoglycemic Drug Product Portfolio
  6. 4.1.5 GSK Recent Developments
  7. 4.2 Takeda
  8. 4.2.1 Takeda Company Information
  9. 4.2.2 Takeda Business Overview
  10. 4.2.3 Takeda Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Takeda Non-Insulin Hypoglycemic Drug Product Portfolio
  12. 4.2.5 Takeda Recent Developments
  13. 4.3 Merck
  14. 4.3.1 Merck Company Information
  15. 4.3.2 Merck Business Overview
  16. 4.3.3 Merck Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Merck Non-Insulin Hypoglycemic Drug Product Portfolio
  18. 4.3.5 Merck Recent Developments
  19. 4.4 Uni-Bio Science Group
  20. 4.4.1 Uni-Bio Science Group Company Information
  21. 4.4.2 Uni-Bio Science Group Business Overview
  22. 4.4.3 Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Product Portfolio
  24. 4.4.5 Uni-Bio Science Group Recent Developments
  25. 4.5 Eli Lilly
  26. 4.5.1 Eli Lilly Company Information
  27. 4.5.2 Eli Lilly Business Overview
  28. 4.5.3 Eli Lilly Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Eli Lilly Non-Insulin Hypoglycemic Drug Product Portfolio
  30. 4.5.5 Eli Lilly Recent Developments
  31. 4.6 Jiangsu Hengrui Medicine
  32. 4.6.1 Jiangsu Hengrui Medicine Company Information
  33. 4.6.2 Jiangsu Hengrui Medicine Business Overview
  34. 4.6.3 Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Product Portfolio
  36. 4.6.5 Jiangsu Hengrui Medicine Recent Developments
  37. 4.7 Jiangsu Hansoh Pharmaceutical
  38. 4.7.1 Jiangsu Hansoh Pharmaceutical Company Information
  39. 4.7.2 Jiangsu Hansoh Pharmaceutical Business Overview
  40. 4.7.3 Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Product Portfolio
  42. 4.7.5 Jiangsu Hansoh Pharmaceutical Recent Developments
  43. 4.8 Pfizer
  44. 4.8.1 Pfizer Company Information
  45. 4.8.2 Pfizer Business Overview
  46. 4.8.3 Pfizer Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Pfizer Non-Insulin Hypoglycemic Drug Product Portfolio
  48. 4.8.5 Pfizer Recent Developments
  49. 4.9 Sumitomo Dainippon Pharma
  50. 4.9.1 Sumitomo Dainippon Pharma Company Information
  51. 4.9.2 Sumitomo Dainippon Pharma Business Overview
  52. 4.9.3 Sumitomo Dainippon Pharma Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Sumitomo Dainippon Pharma Non-Insulin Hypoglycemic Drug Product Portfolio
  54. 4.9.5 Sumitomo Dainippon Pharma Recent Developments
  55. 4.10 Servier
  56. 4.10.1 Servier Company Information
  57. 4.10.2 Servier Business Overview
  58. 4.10.3 Servier Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Servier Non-Insulin Hypoglycemic Drug Product Portfolio
  60. 4.10.5 Servier Recent Developments
  61. 4.11 Novo Nordisk
  62. 4.11.1 Novo Nordisk Company Information
  63. 4.11.2 Novo Nordisk Business Overview
  64. 4.11.3 Novo Nordisk Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Novo Nordisk Non-Insulin Hypoglycemic Drug Product Portfolio
  66. 4.11.5 Novo Nordisk Recent Developments
  67. 4.12 Luye Pharma Group
  68. 4.12.1 Luye Pharma Group Company Information
  69. 4.12.2 Luye Pharma Group Business Overview
  70. 4.12.3 Luye Pharma Group Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Luye Pharma Group Non-Insulin Hypoglycemic Drug Product Portfolio
  72. 4.12.5 Luye Pharma Group Recent Developments
  73. 4.13 Intarcia Therapeutics
  74. 4.13.1 Intarcia Therapeutics Company Information
  75. 4.13.2 Intarcia Therapeutics Business Overview
  76. 4.13.3 Intarcia Therapeutics Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Intarcia Therapeutics Non-Insulin Hypoglycemic Drug Product Portfolio
  78. 4.13.5 Intarcia Therapeutics Recent Developments
  79. 4.14 Geropharm
  80. 4.14.1 Geropharm Company Information
  81. 4.14.2 Geropharm Business Overview
  82. 4.14.3 Geropharm Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Geropharm Non-Insulin Hypoglycemic Drug Product Portfolio
  84. 4.14.5 Geropharm Recent Developments
  85. 4.15 Eurofarma
  86. 4.15.1 Eurofarma Company Information
  87. 4.15.2 Eurofarma Business Overview
  88. 4.15.3 Eurofarma Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Eurofarma Non-Insulin Hypoglycemic Drug Product Portfolio
  90. 4.15.5 Eurofarma Recent Developments
  91. 4.16 Emisphere
  92. 4.16.1 Emisphere Company Information
  93. 4.16.2 Emisphere Business Overview
  94. 4.16.3 Emisphere Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Emisphere Non-Insulin Hypoglycemic Drug Product Portfolio
  96. 4.16.5 Emisphere Recent Developments
  97. 4.17 Dong-A Pharmaceutical
  98. 4.17.1 Dong-A Pharmaceutical Company Information
  99. 4.17.2 Dong-A Pharmaceutical Business Overview
  100. 4.17.3 Dong-A Pharmaceutical Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Dong-A Pharmaceutical Non-Insulin Hypoglycemic Drug Product Portfolio
  102. 4.17.5 Dong-A Pharmaceutical Recent Developments
  103. 4.18 Alkem Labs
  104. 4.18.1 Alkem Labs Company Information
  105. 4.18.2 Alkem Labs Business Overview
  106. 4.18.3 Alkem Labs Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Alkem Labs Non-Insulin Hypoglycemic Drug Product Portfolio
  108. 4.18.5 Alkem Labs Recent Developments
  109. 4.19 3SBio
  110. 4.19.1 3SBio Company Information
  111. 4.19.2 3SBio Business Overview
  112. 4.19.3 3SBio Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 3SBio Non-Insulin Hypoglycemic Drug Product Portfolio
  114. 4.19.5 3SBio Recent Developments
5 Global Non-Insulin Hypoglycemic Drug Market Scenario by Region
  1. 5.1 Global Non-Insulin Hypoglycemic Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Non-Insulin Hypoglycemic Drug Sales by Region: 2021-2032
  3. 5.2.1 Global Non-Insulin Hypoglycemic Drug Sales by Region: 2021-2026
  4. 5.2.2 Global Non-Insulin Hypoglycemic Drug Sales by Region: 2027-2032
  5. 5.3 Global Non-Insulin Hypoglycemic Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global Non-Insulin Hypoglycemic Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global Non-Insulin Hypoglycemic Drug Revenue by Region: 2027-2032
  8. 5.4 North America Non-Insulin Hypoglycemic Drug Market Facts & Figures by Country
  9. 5.4.1 North America Non-Insulin Hypoglycemic Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Non-Insulin Hypoglycemic Drug Sales by Country (2021-2032)
  11. 5.4.3 North America Non-Insulin Hypoglycemic Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Non-Insulin Hypoglycemic Drug Market Facts & Figures by Country
  15. 5.5.1 Europe Non-Insulin Hypoglycemic Drug Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Non-Insulin Hypoglycemic Drug Sales by Country (2021-2032)
  17. 5.5.3 Europe Non-Insulin Hypoglycemic Drug Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.6 Asia Pacific Non-Insulin Hypoglycemic Drug Market Facts & Figures by Country
  24. 5.6.1 Asia Pacific Non-Insulin Hypoglycemic Drug Market Size by Country: 2021 VS 2025 VS 2032
  25. 5.6.2 Asia Pacific Non-Insulin Hypoglycemic Drug Sales by Country (2021-2032)
  26. 5.6.3 Asia Pacific Non-Insulin Hypoglycemic Drug Revenue by Country (2021-2032)
  27. 5.6.4 China
  28. 5.6.5 Japan
  29. 5.6.6 South Korea
  30. 5.6.7 India
  31. 5.6.8 Australia
  32. 5.6.9 China Taiwan
  33. 5.6.10 Southeast Asia
  34. 5.7 South America Non-Insulin Hypoglycemic Drug Market Facts & Figures by Country
  35. 5.7.1 South America Non-Insulin Hypoglycemic Drug Market Size by Country: 2021 VS 2025 VS 2032
  36. 5.7.2 South America Non-Insulin Hypoglycemic Drug Sales by Country (2021-2032)
  37. 5.7.3 South America Non-Insulin Hypoglycemic Drug Revenue by Country (2021-2032)
  38. 5.7.4 Mexico
  39. 5.7.5 Brazil
  40. 5.7.6 Argentina
  41. 5.8 Middle East and Africa Non-Insulin Hypoglycemic Drug Market Facts & Figures by Country
  42. 5.8.1 Middle East and Africa Non-Insulin Hypoglycemic Drug Market Size by Country: 2021 VS 2025 VS 2032
  43. 5.8.2 Middle East and Africa Non-Insulin Hypoglycemic Drug Sales by Country (2021-2032)
  44. 5.8.3 Middle East and Africa Non-Insulin Hypoglycemic Drug Revenue by Country (2021-2032)
  45. 5.8.4 Turkey
  46. 5.8.5 Saudi Arabia
  47. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Non-Insulin Hypoglycemic Drug Sales by Type (2021-2032)
  2. 6.1.1 Global Non-Insulin Hypoglycemic Drug Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Non-Insulin Hypoglycemic Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global Non-Insulin Hypoglycemic Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global Non-Insulin Hypoglycemic Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Non-Insulin Hypoglycemic Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Non-Insulin Hypoglycemic Drug Sales by Application (2021-2032)
  2. 7.1.1 Global Non-Insulin Hypoglycemic Drug Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Non-Insulin Hypoglycemic Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global Non-Insulin Hypoglycemic Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global Non-Insulin Hypoglycemic Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Non-Insulin Hypoglycemic Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Non-Insulin Hypoglycemic Drug Value Chain Analysis
  2. 8.1.1 Non-Insulin Hypoglycemic Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Non-Insulin Hypoglycemic Drug Production Mode & Process
  5. 8.2 Non-Insulin Hypoglycemic Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Non-Insulin Hypoglycemic Drug Distributors
  8. 8.2.3 Non-Insulin Hypoglycemic Drug Customers
9 Global Non-Insulin Hypoglycemic Drug Analyzing Market Dynamics
  1. 9.1 Non-Insulin Hypoglycemic Drug Industry Trends
  2. 9.2 Non-Insulin Hypoglycemic Drug Industry Drivers
  3. 9.3 Non-Insulin Hypoglycemic Drug Industry Opportunities and Challenges
  4. 9.4 Non-Insulin Hypoglycemic Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst